Issued 2026-08-13 at $7.74 · now $7.65 (2026-08-13, −1.2% since)
Based on its own history, a month from the 2026-08-13 close, IBRX has typically landed between $5.18 and $12.76 — a range of −33.1% to +64.8% from the issuance price $7.74.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,756 overlapping 1 month windows · 2015-07-28 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($7.74) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where IBRX has typically landed a month from the 2026-08-13 close of $7.74 — the range is history, not a prediction.
- now $7.65 (-1.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $7.48 (-3.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $6.37–$8.59
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $5.18–$12.76
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-02-08 | −64.9% | −64.9% | +0.0% |
| 2023-02-07 | −64.8% | −64.8% | +0.0% |
| 2023-02-10 | −63.1% | −63.1% | +0.0% |
| 3 best | |||
| 2023-04-11 | +303.9% | −0.6% | +316.2% |
| 2023-04-06 | +290.9% | −6.7% | +290.9% |
| 2023-04-10 | +274.7% | −3.2% | +305.7% |
2,756 overlapping windows · 2015-07-28 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-09-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (source, as of 2026-08-14)
- October 2026 — Trial primary completion: Phase 2 primary completion: A Study to Assess Anktiva in Patients With Long Covid-19. (source, as of 2026-08-14)
- May 2027 — Trial primary completion: Phase 2 primary completion: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (source, as of 2026-08-14)
- 2027-05-25 — Trial primary completion: Phase 2 primary completion: Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (source, as of 2026-08-14)
- September 2028 — Trial primary completion: Phase 3 primary completion: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In (source, as of 2026-08-14)
- 2029-08-31 — Trial primary completion: Phase 2 primary completion: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (source, as of 2026-08-14)
- 2029-12-31 — Trial primary completion: Phase 2 primary completion: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.